Epidermolysis Bullosa (EB) Disease
Vilacto Bio™ treats a wide range of inflammatory abnormalities, inflammation related disorders (both acute and chronic) and is well within the capacity of our patented properties (Lactoactive®).
We have already overcome notorious healing challenges for some of those concerns, like such wounds, psoriasis, vitiligo, and autoimmune related skin conditions. Our products are currently available on the market as Vilact®. Our aim is to develop new drugs and treatment based on our current treatments to help more people suffering from debilitating skin conditions.
Fast Facts in the USA
An estimated 25,000 to 50,000 people have Epidermolysis Bullosa.
An estimated 1 out of every 20,000 live births is affected by some type of EB.
Approximately 200 children a year are born with EB.
Currently there is no treatment or cure.
The average monthly cost for EB patients to acquire vital specialized bandages is $10,000.
Global Fast Facts
An estimated 50 per million live births are diagnosed Epidermolysis Bullosa (EB) Disease.
Of these cases, approximately 92% are epidermolysis bullosa simplex, 5% are dystrophic epidermolysis bullosa, 1% are junctional epidermolysis bullosa, and 2% are unclassified.
Junctional epidermolysis bullosa has an estimated mortality rate of 87% during the first year of life.
It's estimated one in every 17,000 children born in the UK will have EB.
In some cases, death can occur before the age of 30.
The current standard of care for EB costs $10 000 - 15 000 a month, or $120 000 - 180 000/yr.
References
1. http://www.debra.org
2. https://rarediseases.org/rare-diseases/epidermolysis-bullosa/
3. Schmidt E, Zillikens D. The Diagnosis, and Treatment of Autoimmune Blistering Skin Diseases. Deutsches Ärzteblatt International. 2011;108(23):399-405. doi:10.3238/arztebl.2011.0405.
4. http://www.inmedpharma.com/